Literature DB >> 7661154

90% cure: which anti-Helicobacter therapy can achieve this treatment goal?

W A de Boer, G N Tytgat.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7661154

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  3 in total

1.  Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.

Authors:  Yuqin Li; Xiayue Huang; Linhua Yao; Ruihua Shi; Guoxin Zhang
Journal:  Wien Klin Wochenschr       Date:  2010-07-16       Impact factor: 1.704

Review 2.  Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China.

Authors:  Hong Lu; Wei Zhang; David Y Graham
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-10       Impact factor: 2.566

3.  Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates.

Authors:  Anita Paula Ortiz Godoy; Marcelo Lima Ribeiro; Yune Helena Borges Benvengo; Lea Vitiello; Maira de Carvalho Bueno Miranda; Sergio Mendonça; José Pedrazzoli
Journal:  BMC Gastroenterol       Date:  2003-08-11       Impact factor: 3.067
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.